The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R01 - Clinical Trial Optional)

NIH Funding Announcements - Fri, 12/08/2017 - 03:49
Funding Opportunity RFA-HD-19-013 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity Announcement (FOA) is to encourage research into the role of pluripotent progenitor/stem cells in the pathogenesis and treatment of selected gynecologic disorders, specifically uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse.
Categories: NIH-Funding

Promoting Research in Basic Neuroscience (R01)

NIH Funding Announcements - Fri, 12/08/2017 - 03:22
Funding Opportunity PAS-18-483 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related.
Categories: NIH-Funding

Notice of Expiration of PAR-15-289 "The Pancreatic Cancer Detection Consortium (U01)"

NIH Funding Announcements - Fri, 12/08/2017 - 02:39
Notice NOT-CA-18-029 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trials Not Allowed)

NIH Funding Announcements - Thu, 12/07/2017 - 13:56
Funding Opportunity RFA-EY-17-003 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders. This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement therapy. Model systems using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA. An important aspect of this FOA is that the research team is expected to treat the loss of vision associated with the experimental model using an approach that involves regenerating PRCs and/or RGCs and their connections. The choice of cells for therapy might include adult stem cells, precursors, stem cell derived progenitor cells, or conversion of intrinsic cells such as glia. It is expected that quantitative measures will be used to evaluate survival and integration of the regenerated cells using electrophysiology, functional imaging, behavioral measures or any other appropriate technology that would demonstrate circuit integration and restoration of visual function.
Categories: NIH-Funding

Be Careful to Pick the Right Funding Opportunity Announcement (FOA)

Rock Talk: NIH Extramural News - Thu, 12/07/2017 - 12:30

Recent policy changes requiring clinical trial applications to be submitted to FOAs that specifically allow clinical trials, first announced in fall of 2016, impact how all NIH applicants choose a FOA, whether you are submitting a clinical trial or not.

Over the last year, each NIH Institute and Center has been carefully evaluating its research funding priorities and strategic goals and using that information to articulate their funding priorities for clinical trials.  They are communicating their priorities through the funding opportunity announcements they issue.

The requirement to respond to clinical trial specific FOAs begins for applications submitted for due dates on or after January 25, 2018. NIH is reissuing any FOA that will accept clinical trial applications after that date. Many of these FOAs have already been issued, others will be published at least 60 days before the first due date for which they will accept applications. How can you tell which FOAs will allow clinical trials?  Reissued clinical trial FOAs make clinical trial allowability clear in both the title and in section 2, and they include clinical trial review criteria.

Responding to the correct type of FOA ensures that you know what information you are expected to include in your application and that you can develop an application that is responsive to the review criteria. It also ensures that reviewers apply the correct criteria and give your application the best review possible.

Before beginning your search for an FOA, if you are doing human subject research you should use our clinical trial tool to determine whether NIH considers any of your studies a clinical trial.

If any study (or component) of your application meets the NIH definition of a clinical trial (even if your application includes other studies that are not clinical trials), you must respond to a FOA that allows for clinical trials.

If none of your specific aims include studies that meet the NIH definition of a clinical trial, be sure to respond to an FOA that does not require clinical trials. Check section II of the FOA; there will be a row entitled “Clinical Trial?” that should say either “Clinical trials not allowed” or “Clinical trials optional”.

We are re-issuing existing parent announcements as “clinical trial not allowed” for due dates on or after January 25, 2018.  Our most recent reminder notice provides a list of all the parent announcements (old and new) and when they will be reissued. .) . The participating organizations may vary between the “clinical trial not allowed” parent FOA and the “clinical trial required” parent FOA for the same activity code. Read the details of each FOA carefully. Note that some institutes that participate on a “Clinical Trial Required” parent may limit their participation to mechanistic studies. Check the Related Notices section of the FOA for any restrictions.

Some IC’s are using different FOAs for different kinds of trials.  We encourage you to visit individual IC’s web pages for guidance.

Note that even for resubmissions, revisions or renewals, you may need to find a new FOA to apply to with the appropriate clinical trial allowability that reflects the research in the application you are submitting.

The upshot of all this?  The FOA landscape is changing. It is important to pick your FOA carefully. We will be reissuing all parent FOAs and all FOAs that will allow clinical trials at least 60 days before the first due date. Before you are ready to apply, check back to be sure you are responding to the latest version of the FOA, and to read any related notices that have been issued since you first looked at the FOA. Learn more about understanding funding opportunities and NIH clinical trial requirements on the NIH Grants and Funding website. And be on the lookout for a new video we will be putting out in the next few weeks on finding and understanding funding opportunities.

Categories: NIH-Funding

Prevention and Treatment Research to Address HIV/AIDS Disparities in Women in the US (R01-Accepting applications that either propose or do not propose clinical trial(s))

NIH Funding Announcements - Thu, 12/07/2017 - 12:08
Funding Opportunity RFA-MD-18-004 from the NIH Guide for Grants and Contracts. This initiative will support health services, intervention, and implementation research to understand and reduce racial/ethnic, geographic, and socioeconomic HIV disparities in US women. Projects may address HIV prevention, screening and diagnosis, and/or treatment. Projects may involve primary data collection and/or secondary analysis of existing data.
Categories: NIH-Funding

Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R01- Clinical Trial Required)

NIH Funding Announcements - Thu, 12/07/2017 - 12:05
Funding Opportunity PAR-18-479 from the NIH Guide for Grants and Contracts. This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. This FOA is published in parallel to a companion R34 FOA (PAR-xx-xxx) supporting pilot studies in preparation for the larger-scale studies described here.
Categories: NIH-Funding

Notice of Correction for PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)

NIH Funding Announcements - Thu, 12/07/2017 - 11:20
Notice NOT-TR-18-012 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Correction to Funding Opportunity Description for RFA-HL-16-025 "NHLBI Emerging Investigator Award (EIA) (R35)"

NIH Funding Announcements - Thu, 12/07/2017 - 11:08
Notice NOT-HL-17-569 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) - Clinical Trial Required

NIH Funding Announcements - Thu, 12/07/2017 - 10:59
Funding Opportunity PAR-18-486 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of award.
Categories: NIH-Funding